Latest Conference Articles

September 20th 2023, 6:03pm

International Liver Cancer Association Annual Conference

Second-line treatment with regorafenib displayed safety in patients with advanced hepatocellular carcinoma who were not eligible for treatment on the phase 3 RESORCE trial, according to data from the phase 2 REGAIN trial.

September 19th 2023, 6:36pm

International Liver Cancer Association Annual Conference

The addition of toripalimab to standard-of-care sorafenib in the frontline setting demonstrated preliminary efficacy and tolerability in patients with unresectable hepatocellular carcinoma.

September 19th 2023, 2:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Uwe Platzbecker, MD, discusses how the FDA approval of luspatercept for the treatment of anemia in patients who have not had prior treatment with erythropoiesis-stimulating agent and may require regular red blood cell transfusions could change the sequencing of agents for this patient population.

September 16th 2023, 10:00am

International Liver Cancer Association Annual Conference

The phase 2 ACTION trial, which evaluated the safety of second-line cabozantinib in patients with hepatocellular carcinoma who were intolerant to first-line sorafenib or who received agents other than sorafenib in the first line, did not meet its safety futility criteria, allowing the trial to continue.

September 15th 2023, 5:00pm

International Liver Cancer Association Annual Conference

Tissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression on frontline atezolizumab and bevacizumab to targeted therapy or another TKI based on identified genomic alterations.

September 15th 2023, 1:04pm

International Liver Cancer Association Annual Conference

The use of an immuno-oncology regimen as systemic therapy was found to be an independent prognostic factor and was associated with improved long-term survival for patients with hepatocellular carcinoma, regardless of IO’s sequencing in the first and later lines of treatment.

September 14th 2023, 2:00pm

Anna Minchom, MB BCh, MRCP, MD, discusses the need to develop an amivantamab administration method that decreases the likelihood of infusion-related reactions in patients with solid tumors, revealed the RP2D of subcutaneous amivantamab that was determined in the PALOMA trial, and emphasized potential future directions with this agent.

September 13th 2023, 7:25pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Patient preferences should be considered when selecting the optimal treatment regimen for patients with relapsed/refractory follicular lymphoma, as both CD19-directed CAR T-cell therapies and CD20-targeted bispecific antibodies can be efficacious in this population, according to a presentation by Caron A. Jacobson, MD, MMSc, at the 2023 SOHO Annual Meeting.

September 13th 2023, 4:36pm

International Liver Cancer Association Annual Conference

Neoadjuvant treatment with the combination of nivolumab and ipilimumab led to responses and was well tolerated in patients with resectable hepatocellular carcinoma.

September 12th 2023, 8:46pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Efforts to widen the treatment armamentarium for patients with mantle cell lymphoma have been thwarted by increased toxicities and resistance mechanisms with effective therapies such as BTK inhibitors.

September 12th 2023, 8:26pm

International Liver Cancer Association Annual Conference

Real-world data from a systemic review of treatment patterns in the United States showed that the majority of patients with hepatocellular carcinoma administered atezolizumab and bevacizumab in the frontline setting discontinued treatment within 12 months, indicating the need for additional research on the effectiveness of this regimen for patients with high-risk disease.

September 12th 2023, 7:18pm

International Liver Cancer Association Annual Conference

Treatment with ramucirumab in the second line after first-line lenvatinib monotherapy or the combination of atezolizumab and bevacizumab, or as third-line treatment following both regimens, elicited efficacy comparable with second-line ramucirumab following treatment with sorafenib in patients with advanced hepatocellular carcinoma.

September 12th 2023, 6:34pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Following the FDA approvals of the JAK inhibitors ruxolitinib, fedratinib, and pacritinib, the treatment landscape of myelofibrosis continues to grow with the use of these agents with an additional FDA review planned for momelotinib in September 2023.

September 12th 2023, 4:05pm

Natasha B. Leighl, BSc, MMSc, MD, discusses efficacy findings with the EGFR/MET inhibitor amivantamab in patients with advanced non–small cell lung cancer harboring MET exon 14 skipping mutations.

September 12th 2023, 3:55pm

Ticiana Leal, MD, discusses the rationale for and findings from a PD-L1 subgroup analysis of the phase 3 LUNAR trial in patients with metastatic non–small cell lung cancer.

September 11th 2023, 11:25pm

IASLC World Conference on Lung Cancer

The addition of atezolizumab to bevacizumab, carboplatin, and pemetrexed or paclitaxel (ABCP) did not result in a statistically significant improvement in progression-free survival vs BCP for patients with metastatic nonsquamous non–small cell lung cancer in the first line, missing the primary end point of the phase 3 IMpower151 study.

September 11th 2023, 10:30pm

Marcelo Vailati Negrao, MD, discusses efficacy findings from the phase 1b/2 KontRASt-01 trial (NCT04699188) in patients with KRAS G12C–mutated solid tumors.

September 11th 2023, 10:10pm

Shirish M. Gadgeel, MD, discusses 2-year follow-up data from the phase 1/2 KRYSTAL-1 trial in patients with advanced or metastatic non–small cell lung cancer harboring KRAS G12C mutations.

September 11th 2023, 8:46pm

IASLC World Conference on Lung Cancer

Treatment with durvalumab plus tremelimumab and chemotherapy led to higher rates of long-term clinical benefit compared with chemotherapy alone in the treatment of patients with first-line metastatic non–small cell lung cancer.

September 11th 2023, 7:11pm

IASLC World Conference on Lung Cancer

The addition of perioperative durvalumab to neoadjuvant chemotherapy led to a significant improvement in terms of pathological complete response and event-free survival compared with placebo plus chemotherapy in patients with resectable non–small cell lung cancer.